Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

NCT07188558 is registered in ClinicalTrials.gov with Lyell Immunopharma, Inc. as lead sponsor.

NCT NCT07188558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07188558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting
Lead sponsor
Lyell Immunopharma, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
January 12, 2026
Completion date
January 31, 2032
Enrollment
400 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma (dlbcl), diffuse large b cell lymphoma refractory, diffuse large b cell lymphoma relapsed, large b-cell lymphoma, lymphoma, b-cell, non-hodgkin lymphoma, non-hodgkin lymphoma refractory/ relapsed, refractory non-hodgkin lymphoma, relapsed non-hodgkin lymphoma